Purinex, Inc

11 Pages Posted: 21 Oct 2008

See all articles by Robert F. Bruner

Robert F. Bruner

University of Virginia - Darden School of Business

Sean Carr

University of Virginia - Darden School of Business

Multiple version iconThere are 2 versions of this paper

Abstract

In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug. The company, however, had no sales or earnings and only 11 months of cash on hand. The student must assess whether the company should attempt to secure financing now or wait until it consummated a partnership deal. The tasks for the student include evaluating the probabilities that collaboration with a pharmaceutical company would actually happen; determining whether the company stay above water until such occurred; and analyzing the other risks to the company under these circumstances.

Excerpt

UVA-F-1491

Version 4.2

PURINEX, INC.

To lead the world in discovering, developing & commercializing novel therapeutic compounds acting on the purine receptors in order to save and improve patients' lives.

—Company mission statement

In June 2004, Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, had reached a turning point. Sometime in the next four to 12 months, the company stood an excellent chance of securing a partnership with a major pharmaceutical company. That partnership, if secured, would enable Purinex to develop one of its leading compounds into a drug for the treatment of one of the world's deadliest and most widespread diseases. The company had no sales or earnings, however, and there was only enough cash on hand to last 11 months.

. . .

Keywords: investment analysis, capital budgeting, financing investment analysis venture capital, early-stage financing

Suggested Citation

Bruner, Robert F. and Carr, Sean, Purinex, Inc. Darden Case No. UVA-F-1491, Available at SSRN: https://ssrn.com/abstract=1279943

Robert F. Bruner (Contact Author)

University of Virginia - Darden School of Business ( email )

P.O. Box 6550
Charlottesville, VA 22906-6550
United States
434-924-3823 (Phone)
434-924-0714 (Fax)

HOME PAGE: http://faculty.darden.edu/brunerb/

Sean Carr

University of Virginia - Darden School of Business ( email )

P.O. Box 6550
Charlottesville, VA 22906-6550
United States
434-924-4812 (Phone)

HOME PAGE: http://www.batteninstitute.org

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
91
Abstract Views
1,041
rank
37,005
PlumX Metrics